Annual report pursuant to Section 13 and 15(d)

Royalty and Commercial Payment Purchase Agreements - Aronora (Details)

v3.24.0.1
Royalty and Commercial Payment Purchase Agreements - Aronora (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Apr. 07, 2019
USD ($)
item
Sep. 30, 2019
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs     $ 14,650 $ 8,000
Contingent consideration under RPAs, AAAs and CPPAs     7,000 75
Short-term royalty and commercial payment receivables     14,215 $ 2,366
Aronora | Royalty Purchase Agreement        
Agreements        
Number of drug candidates | item 5      
Non-royalties to be received (as a percent) 10.00%      
Future non-royalty payments to be received (as a percent) 5.00%      
Multiplier for cumulative amount of consideration paid | item 2      
Payments of consideration under RPAs, AAAs and CPPAs $ 6,000 $ 3,000    
Threshold amount of cumulative royalties on net sales per product 250,000      
Maximum royalty milestone payments to be paid per product 85,000      
Acquisition of royalty and commercial payment receivables, Long-Term 9,000      
Contingent consideration under RPAs, AAAs and CPPAs 3,000      
Amount of allowance for credit losses     $ 0  
Aronora | Royalty Purchase Agreement | Minimum        
Agreements        
Threshold amount of cumulative royalties on net sales per product 25,000      
Aronora | Royalty Purchase Agreement | SVB Loan        
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs $ 3,000      
Aronora | Royalty Purchase Agreement | Bayer Products        
Agreements        
Number of drug candidates | item 3      
Number of drug candidates subject to exclusive license option | item 1      
Royalties entity has right to receive (as a percent) 100.00%      
Non-royalties to be received (as a percent) 10.00%      
Contingent future cash payment for each product $ 1,000      
Aronora | Royalty Purchase Agreement | Bayer Products | Maximum        
Agreements        
Contingent consideration under RPAs, AAAs and CPPAs $ 3,000      
Aronora | Royalty Purchase Agreement | Non-Bayer Products        
Agreements        
Number of drug candidates | item 2      
Non-royalties to be received (as a percent) 10.00%